

Urinary incontinence and pelvic organ prolapse in women: management Guideline Committee meeting 2

Date: 08/06/2017

Location: RCOG, London

Minutes: CONFIRMED



Committee members present:		
Fergus Macbeth (Chair)		(Present for notes 1 – 7)
Rohna Kearney (Topic advisor)		(Present for notes 1 – 7)
Karen Ward (Topic advisor)		(Present for notes 1 – 7)
Suzanne Biers		(Present for notes 1 – 7)
Jacqueline Emkes		(Present for notes 1 – 7)
Polly Harris		(Present for notes 1 – 7)
Catherine Heffernan		(Present for notes 3 – 7)
Sarah Love-Jones		(Present for notes 1 – 7)
Doreen McClurg		(Present for notes 1 – 7)
Vikky Morris		(Present for notes 1 – 7)
Carmel Ramage		(Present for notes 1 – 7)
Julian Spinks		(Present for notes 1 – 7)
Lucy Ryan		(Present for notes 1 – 7)
Kate Welford		(Present for notes 1 – 7)

In attendance:		
Andrew Harding	NICE Guideline Commissioning Manager	(Present for notes 1 – 7)
Judy McBride	NICE Senior Medical Editor	(Present for notes 1 – 4)
Lisa Boardman	NGA Guideline Lead	(Present for notes 1 – 7)
Shona Burman-Roy	NGA Senior Systematic Reviewer	(Present for notes 1 – 7)
Melanie Davies	NGA Clinical Advisor	(Present for notes 1 – 7)
Elise Hasler	NGA Information Scientist	(Present for notes 4 – 5)

Committee minutes

Sally Humphreys	NGA Project Manager	(Present for notes 1 – 7)
Charlotte Mahoney	NGA Clinical Fellow	(Present for notes 1 – 7)
Eric Slade	NGA Health Economist	(Present for notes 1 – 7)
Fiona Whiter	Systematic Reviewer	(Present for notes 1 – 5)

Apologies:

Anthony Dixon	Co-opted Committee member
James Stephenson	Co-opted Committee member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the third meeting on urinary incontinence and pelvic organ prolapse in women: management. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: learning about writing a NICE guideline, reviewing the evidence and drafting recommendations, and discussing and amending review question protocols.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was urinary incontinence and pelvic organ prolapse in women: management.

The Chair asked everyone to verbally declare any interests that have arisen since appointment or that were specific to the topics being considered at this meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Anthony Dixon	Consultant Surgeon & Reader Colorectal and Pelvic Floor Surgery, North Bristol, NHS Trust	25.5.2017 Speaking in Seattle in June 2017 about how to avoid complications in lap central mesh rectopexy, and running a cadaver	Personal financial (within policy) non-specific	Declare and continue

Committee minutes

		operating training session (receives a contribution to costs of flight from American Society of Colorectal Surgeons)		
Jacqueline Emkes	Lay member	8.6.2017 Invited by the charity Bladder Health UK to contribute quotes for Hearst UK magazine on the experience of continence health problems	Personal non-financial specific	Declare and continue
Polly Harris	Clinical Lead/Specialist Nurse, Bladder & Bowel Service, Accrington	8.6.2017 Attended a hospital MDT where lunch was provided with a presentation of pessary devices by Medi Plus. ("I do not use this type of device in my practice as it is not within the service specification to manage POP.")	Non-personal financial specific	Declare and continue
Rohna Kearney	Consultant Urogynaecologist, Warrell Unit, St Mary's Hospital, Central Manchester Foundation Trust	22.5.2017 Member of United Kingdom Continence Society committee on standardisation of urodynamic practice	Personal non-financial specific	Declare and continue
Karen Ward	Consultant Gynaecologist, Warrell Unit, St Mary's Hospital, Central	6.6.2017 Vice Chair of UK Continence society – April 2017	Personal non-financial specific	Declare and continue

	Manchester University Hospital NHS Trust			
<p>The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.</p>				
<p>3. Minutes of last meeting</p>				
<p>The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.</p> <p>The Chair confirmed that all matters arising had been completed or were in hand.</p>				
<p>4. Presentations</p>				
<p>The Chair introduced Judy McBride, NICE Senior Medical Editor, who gave a presentation on Writing NICE guidelines.</p> <p>The Chair introduced Shona Burman-Roy, NGA Senior Systematic Reviewer, Fiona Whiter, Systematic Reviewer, and Eric Slade, NGA Health Economist, who gave a presentation on EVIDENCE REVIEW: 4.2 What is the most effective initial dose of botulinum toxin type A for treating overactive bladder?</p> <p>The Chair introduced Shona Burman-Roy, NGA Senior Systematic Reviewer, and Fiona Whiter, Systematic Reviewer, who gave a presentation on EVIDENCE REVIEW: 4.1 What is the value of urodynamic assessment before botulinum toxin type A treatment?</p> <p>The Chair introduced Shona Burman-Roy, NGA Senior Systematic Reviewer, who gave a presentation on PROTOCOL: 8.1 What lifestyle interventions are effective for managing pelvic organ prolapse?</p> <p>The Chair introduced Shona Burman-Roy, NGA Senior Systematic Reviewer, who gave a presentation on PROTOCOL: 8.2 What is the effectiveness of topical oestrogen for managing pelvic organ prolapse with vaginal atrophy?</p> <p>The Chair introduced Shona Burman-Roy, NGA Senior Systematic Reviewer, who gave a presentation on PROTOCOL: 8.3 What are the most effective conservative management options (for example, pelvic floor exercises and pessaries) for pelvic organ prolapse?</p> <p>The Chair introduced Eric Slade, NGA Health Economist, who gave a presentation on HEALTH ECONOMICS: Update on 8.4 and 5.1 network meta-analyses (NMAs)</p>				

and economic plan.

The speakers took questions from the group. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked the speakers for their presentations.

5. Questions and discussion

The Committee discussed the presentations and were given the opportunity to ask questions, draft recommendations and rationale and impact sections following evidence reviews, and agree amendments to the review protocols and economic plans.

6. Other issues

The Committee considered the following equalities issues:

- No issues were raised at this meeting.

The Committee considered the following implementation issues:

- No specific issues were raised at this meeting.

7. AOB

The Committee were informed of a communication from NICE asking the group to carefully consider the existing recommendation which lists a specific type of mesh material, as this has the potential to restrict medical device selection and development. The Guideline Committee agreed to note this when reviewing the evidence where applicable.

Date of next meeting: 18/07/2017

Location of next meeting: RCOG, London